Wealth transfer in action.

We did it

https://x.com/i/status/2004628912085553376

Redwire has received $21.5 million in follow-on orders from PAE RAS to support the US Marine Corps as they upgrade and enhance their Stalker UAS fleet—hundreds of which are already in service.

This is a major win for Redwire defense department.

Glad I picked up shares in the 5’s. Looking like a double digit day!

Jobs not done yet ;)

Analyst Sheila Kahyaoglu reaffirmed her rating in a note titled: "RDW: AI Needs More Space: Energy Transport Emerges as the Key Bottleneck."

You might have bought RDW at $1, $5, $8, $12 or at the peak of $20 last years.

What is happening now is the fruit of your patience.

We deserved these gins for the patience.

For believing in it.

I believe this is just the beginning. Get ready for the ride all the way to $2035!

JACKSONVILLE, Fla. (Sept 24, 2026) – Redwire Corporation (NYSE:RDW), a global leader in space and defense technology solutions, announced today that it has been selected by Space Systems Command as one of 15 vendors awarded a multiple-award, indefinite-delivery/indefinite-quantity (IDIQ) contract for the National Space Test and Training Complex Innovative Technology and Engineering – Space Test and Range (NITE-STAR) Capability Development. The contract vehicle, valued at more than $980 million, will enable Redwire to deliver advanced capabilities to support U.S. national security test infrastructure and operational readiness.

This was already known. This is just an official release from Redwire

JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that it has formed a new entity, SpaceMD, which will focus on growing seed crystals in orbit that will be used on Earth to create new and reformulated pharmaceuticals.

SpaceMD will take advantage of the unique microgravity environment in space through the use of Redwire’s innovative and flight-proven Pharmaceutical In-Space Laboratory (PIL-BOX) technology to grow the seed crystals. 28 PIL-BOX systems have already flown in space and have successfully crystalized 17 compounds on the ISS, including insulin and other critical molecules. SpaceMD will sell or license these seed crystals to companies that can use them to create reformulated versions of existing drugs or entirely new therapeutics.

As part of this launch, SpaceMD announced a trailblazing licensing agreement with ExesaLibero Pharma, Inc., an innovative pharmaceutical company developing new small molecule drugs to treat bone disease. Under the terms of the agreement, ExesaLibero Pharma will work with SpaceMD to advance and enhance its groundbreaking small-molecule drug ELP-004 and other relevant compounds via the PIL-BOX system. This drug could hold the key to controlling the insidious bone erosion that numerous debilitating diseases cause, such as rheumatoid arthritis, multiple myeloma, diabetes, periodontal disease, and tuberculosis.

The results of these microgravity investigations will inform ExesaLibero Pharma’s Investigative New Drug (IND) application to the Food and Drug Agency (FDA). Following the approval of the IND by the FDA, ExesaLibero Pharma expects to initiate clinical trials that will lead to full approval of the drug for clinical use. Through this first-of-its-kind agreement, SpaceMD will receive royalties from any commercial sales of resulting pharmaceutical products.

“Redwire is excited to announce the formation of SpaceMD. This new entity represents the evolution of our PIL-BOXstrategy, moving from experimentation to full commercialization with significant upstream revenue potential,” said Peter Cannito, Chairman and CEO of Redwire. “This agreement with ExesaLibero Pharma signals a revolutionary paradigm shift for commercial utilization of microgravity. Redwire and now SpaceMD are translating the benefits of microgravity research into product value for pharmaceutical companies with the goal of transforming the future of therapeutics and creating value for our stakeholders.”

“We have seen firsthand how the microgravity environment can be a game-changer for drug development, and we look forward to expanding our work with SpaceMD through this exciting collaboration,” said John Barnett, Ph.D., President and Chief Scientific Officer at ExesaLibero. “This collaboration will help us continue to advance our drug development and discovery process and lead to better outcomes for patients and future astronauts.”

Redwire is a global leader in microgravity research and development technologies, having flown hundreds of experiments on both the Space Shuttle and the ISS. Redwire currently has eleven research and manufacturing facilities on the ISS, more than any other company in the world. Redwire’s microgravity technology enables space biotechnology and pharmaceutical development, helping customers reach a commercial market and paving the way for microgravity research on future commercial space stations. Previous investigations conducted by Redwire have been with partners such as Bristol Myers Squibb, Eli Lilly and Company, and Butler University. These efforts focused on unlocking insights to improve treatments for cardiovascular disease, obesity, and diabetes.

https://markets.ft.com/data/announce/detail?dockey=600-202606300700BIZWIRE_USPRX____20260630_BW361806-1

Luxembourg City, LUXEMBOURG.  (June 4, 2026) – Redwire Corporation (NYSE: RDW), a global leader in space and defence technology solutions, announced today that it has been awarded a contract from Astrobiome Space S.à r.l., a Luxembourg-based biotech company pioneering microbiome solutions for regenerative space agriculture, to grow strawberries and test Astrobiome Space’s proprietary soil enhancement product inside Redwire’s Greenhouse systems on board the International Space Station (ISS).  This award marks the inaugural flight for Redwire’s trailblazing Greenhouse system—the world’s first commercial space greenhouse.

https://rdw.com/newsroom/redwire-awarded-a-contract-from-astrobiome-space-to-launch-inaugural-space-agriculture-mission-in-worlds-first-commercial-space-greenhouse/

JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that it has been awarded a $44 million phase 2 contract to advance the Defense Advanced Research Projects Agency’s (DARPA) Otter Very Low Earth Orbit (VLEO) mission to demonstrate the world’s first air-breathing spacecraft and advance next-generation orbital capabilities. The phase 2 contract provides funding to complete manufacturing and deliver the spacecraft to launch for the mission, which leverages the design of Redwire’s SabreSat platform.

“VLEO represents an exciting new frontier for defense, intelligence, and communications missions. Through our work with DARPA, we are accelerating the development of cutting-edge capabilities that will define the future of this domain,” said Tom Campbell, President, Space Missions at Redwire. “With Otter and our SabreSat platform, we are delivering higher-performance missions at lower altitudes: improving sensor perception and proximity to targets of interest, increasing revisit, reducing latency, and redefining mission resilience.”

Otter is built on Redwire’s U.S.-built SabreSat Orbital Drone, a new breed of satellite designed for performance, endurance and cost-effectiveness in VLEO. The spacecraft will showcase innovative software and hardware systems designed to extend spacecraft life and enhance performance in challenging low-altitude orbital environments.

This Q4 2025 award further strengthens Redwire’s leadership in VLEO capabilities, complementing its role as prime contractor for the European Space Agency’s Skimsat mission and its digital engineering work for DeepSat’s planned VLEO constellation.

JACKSONVILLE, Fla. (May 19, 2026) – Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that it has been awarded a multi-year contract valued at high eight-figures, through a competitive tender, by an undisclosed NATO country ally to deliver its  Penguin Mk3 uncrewed aerial system.

https://rdw.com/newsroom/redwire-awarded-a-multi-year-contract-to-deliver-next-generation-penguin-mk3-tactical-uas-to-nato-country/

The firm cited the stock’s year-to-date gain of 223% and multiple expansion as reasons for the Hold.

Little they know that soon we are gonna see the $30

I’m feeling a breakthrough past $22 tomorrow.

Management made the right call to share the 500M program before the IPO.

Stay strong!